ArticleAmerican journal of nephrology2016
Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.
Article in American journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Distinct longitudinal trajectories of alkaline phosphatase and parathyroid hormone at dialysis initiation predict mortality in incident hemodialysis patients.BMC nephrology · 2026Article
- Intra-individual fluctuations in alkaline phosphatase predict mortality and CKD progression: insights from a large CKD cohort.Clinical kidney journal · 2026Article
- Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease-mineral and bone disorder.Clinical kidney journal · 2024Article
- Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.Nutrients · 2022Review
- Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.Journal of nephrology · 2022Review
- Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.American journal of nephrology · 2022Article
- The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients.Renal failure · 2021Article
- The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).Nutrients · 2021Review
- Association between vitamin D levels and mortality in hemodialysis patients: a cohort study.Renal failure · 2020Article
- Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.BMC nephrology · 2020Observational
- Characteristics of patients at initiation of renal replacement therapy - experience of a hemodialysis center.Experimental and therapeutic medicine · 2020Article
- Serum alkaline phosphatase levels correlate with long-term mortality solely in peritoneal dialysis patients with residual renal function.Renal failure · 2019Article
- Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.Journal of bone and mineral metabolism · 2019Article
- Identifying risk groups of infectious spondylitis in patients with end-stage renal disease under hemodialysis: a propensity score-matched case-control study.BMC nephrology · 2019Article
- Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives.International journal of nephrology and renovascular disease · 2019Review
- Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.Drugs · 2018Review
- Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients.Scientific reports · 2017Article
- Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.Nature reviews. Nephrology · 2017Review
- Modeling longitudinal data and its impact on survival in observational nephrology studies: tools and considerations.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
- Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAbnormalities in mineral and bone disorder (MBD) markers are common in patients with chronic kidney disease. However, previous studies have not accounted for their changes over time, and it is unclear whether these changes are associated with survival.
methodsWe examined the association of change in MBD markers (serum phosphorus (Phos), albumin-corrected calcium (Ca(Alb)), intact parathyroid hormone (iPTH) and alkaline phosphatase (ALP)) during the first 6 months of hemodialysis (HD) with all-cause mortality across baseline MBD strata using survival models adjusted for clinical characteristics and laboratory measurements in 102,754 incident HD patients treated in a large dialysis organization between 2007 and 2011.
resultsAcross all MBD markers (Phos, Ca(Alb), iPTH and ALP), among patients whose baseline MBD levels were higher than the reference range, increase in MBD levels was associated with higher mortality (reference group: MBD level within reference range at baseline and no change at 6 months follow-up). Conversely, decrease in Phos and iPTH, among baseline Phos and iPTH levels lower than the reference range, respectively, were associated with higher mortality. An increase in ALP was associated with higher mortality across baseline strata of ALP ≥80 U/l. However, patients with baseline ALP <80 U/l trended towards a lower risk of mortality irrespective of the direction of change at 6 months follow-up.
conclusionsThere is a differential association between changes in MBD markers with mortality across varying baseline levels in HD patients. Further study is needed to determine if consideration of both baseline and longitudinal changes in the management of MBD derangements improves outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.